• reimbursement for hemophilia services and treatments Medicaid reimbursement for treatments for hemophilia patients S.3233/HR5952 Hemophilia SNF Access Act. Medicare, Medicaid and other policy changes due to the COVID emergency. Medicare Coverage and Reimbursement of drugs Medicaid coverage policy S.2543, Prescription Drug Price Relief Act HR. 3 Lower Drug Costs Now Act of 2019 Surprise medical billing
• Implementation of the Affordable Care Act S 1895, Lower Healthcare Cost Act S.2543, Prescription Drug Price Relief Act HR. 3 Lower Drug Costs Now Act of 2019
• Hemophilia research, prevention, surveillance and service programs and issues
• Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs.
• Funding for Hemophilia program FY 2020 Labor, HHS and Education Appropriations

Duration: July 1, 2011 to March 31, 2020

General Issues: Medicare/Medicaid, Insurance, Medical/Disease Research/Clinical Labs, Pharmacy, Budget/Appropriations

Spending: about $1,750,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2011: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Office of Management & Budget (OMB)